$39.94
0.03% yesterday
Nasdaq, Nov 26, 10:00 pm CET
ISIN
US14843C1053
Symbol
CSTL

Castle Biosciences Inc Stock price

$39.94
+15.98 66.69% 1M
+23.84 148.07% 6M
+13.29 49.87% YTD
+9.37 30.65% 1Y
+19.33 93.79% 3Y
-3.66 8.39% 5Y
+18.54 86.64% 10Y
+18.54 86.64% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.01 0.03%

Key metrics

Basic
Market capitalization
$1.2b
Enterprise Value
$888.7m
Net debt
positive
Cash
$287.5m
Shares outstanding
29.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.4 | 3.6
EV/Sales
2.6 | 2.7
EV/FCF
35.0
P/B
2.5
Financial Health
Equity Ratio
85.8%
Return on Equity
4.0%
ROCE
-6.9%
ROIC
-8.8%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$343.5m | $324.0m
EBITDA
$4.1m | $21.6m
EBIT
$-34.9m | $-71.7m
Net Income
$-12.2m | $-53.8m
Free Cash Flow
$25.4m
Growth (TTM | estimate)
Revenue
10.2% | -2.5%
EBITDA
-58.0% | -0.6%
EBIT
-3,265.4% | -927.4%
Net Income
-301.3% | -395.0%
Free Cash Flow
-26.5%
Margin (TTM | estimate)
Gross
79.9%
EBITDA
1.2% | 6.7%
EBIT
-10.2%
Net
-3.6% | -16.6%
Free Cash Flow
7.4%
More
EPS
$-0.4
FCF per Share
$0.9
Short interest
6.1%
Employees
761
Rev per Employee
$440.0k
Show more

Is Castle Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,049 stocks worldwide.

Castle Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Castle Biosciences Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a Castle Biosciences Inc forecast:

Buy
93%
Hold
7%

Financial data from Castle Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
344 344
10% 10%
100%
- Direct Costs 69 69
22% 22%
20%
275 275
8% 8%
80%
- Selling and Administrative Expenses 221 221
15% 15%
64%
- Research and Development Expense 50 50
6% 6%
14%
4.12 4.12
58% 58%
1%
- Depreciation and Amortization 39 39
260% 260%
11%
EBIT (Operating Income) EBIT -35 -35
3,265% 3,265%
-10%
Net Profit -12 -12
301% 301%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about Castle Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Castle Biosciences Inc Stock News

Neutral
GlobeNewsWire
10 days ago
FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chronicle as a Houston Top Workplace, which celebrates people-focused, standout workplace cultures. This marks the fifth consecutive year the Company has been ranked ...
Neutral
GlobeNewsWire
13 days ago
Castle will present new data showing the clinical value of DecisionDx-Melanoma in improving sentinel lymph node biopsy decision making at Dermato-Onco2025.
Neutral
GlobeNewsWire
16 days ago
Castle Biosciences' executive management will present a company overview at the Piper Sandler 37th Annual Healthcare Conference on 12/2/25 at 1:10pm ET
More Castle Biosciences Inc News

Company Profile

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Head office United States
CEO Derek Maetzold
Employees 761
Founded 2007
Website castlebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today